Higher US inflation expectations and rising Treasury yields are putting pressure on many growth stocks. That can push some investors toward cheaper corners of the market where balance sheets still look sound. The Financially Fit Penny Stocks screener focuses on lower priced stocks with healthier finances, which can matter more when money is not as cheap. This article highlights three such candidates and explains why they may deserve a closer look now.

The stocks in the article below are just a starting sample, and the full Financially Fit Penny Stocks screen surfaced 317 more companies with equally compelling stories that are not covered here. Head straight into the Financially Fit Penny Stocks screener to identify, filter and analyze the highest conviction ideas from that wider list.

Ardelyx (ARDX)

Overview: Ardelyx is a biopharmaceutical company that develops and sells medicines for patients with digestive and kidney conditions, including IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for chronic kidney disease patients on dialysis who need to manage high phosphorus levels. The company focuses on treatments that address specific unmet medical needs in the United States and internationally.

Operations: Ardelyx currently generates all of its roughly $450.9 million in revenue from the development and commercialization of its biopharmaceutical products.

Market Cap: US$1.01b

Ardelyx is attracting attention because it sits at the intersection of strong demand for kidney and gastrointestinal treatments and a stock price that screens as inexpensive on several measures. Revenue from IBSRELA and XPHOZAH has reached record quarterly levels, yet the company is still working through payer hurdles and remains loss making, which creates both risk and room for sentiment to shift if access improves. Analysts see a path to profitability by 2027 and point to a high forecast return on equity, while current valuation signals suggest the market is pricing in a lot of caution. In addition, there has been meaningful insider selling and the business relies on a narrow product set, which together create a setup that rewards careful due diligence.

Ardelyx sits at the crossroads of record product revenue and a stock that still prices in caution, which raises a key question about what the market might be missing in the analyst forecasts for Ardelyx.

Build your own Ardelyx style screener

Ardelyx and the two other stocks in this list all came out of the same set of filters, and the real value for you is shaping those filters around what matters most. Use our flexible Screener to mix valuation, future growth and balance sheet metrics, or jump straight into our curated Investing Ideas.

Clover Health Investments (CLOV)

Overview: Clover Health Investments provides Medicare Advantage insurance plans in the United States and offers preferred provider organization and health maintenance organization products to Medicare eligible individuals, supported by its Clover Assistant software platform that helps physicians detect, identify and manage chronic diseases.

Operations: Clover Health Investments generates all of its approximately US$2.48b in revenue from insurance activities in the United States.

Market Cap: US$2.44b

Clover Health Investments offers a mix of fast growing Medicare Advantage membership, a technology driven care model through Clover Assistant, and early signs of a shift toward consistent profitability. Management has raised full year 2026 revenue and GAAP net income guidance after a strong Q2. Some investors view the current share price as below certain estimates of fair value, which can appeal to value focused investors. At the same time, there are real risks to weigh, including exposure to Medicare reimbursement changes, rising medical costs and a funding base that leans on external borrowing. That combination of improving earnings, differentiated technology and meaningful policy and cost risks is what makes Clover a candidate for closer examination in this screener.

Clover Health Investments looks like a story of improving earnings that the market has not fully priced in yet. Scan the 4 key rewards and 1 important warning sign to see how that potential upside sits alongside the policy and cost pressures that could change the picture fast.

Hyliion Holdings (HYLN)

Overview: Hyliion Holdings designs and develops the KARNO Power Module, a fuel flexible generator that can provide distributed electricity using fuels such as natural gas, propane, diesel, waste gases and zero carbon options like renewable hydrogen and ammonia for stationary and mobile applications.

Operations: Hyliion Holdings generates all of its roughly $9 million in revenue from Auto Parts & Accessories in the United States.

Market Cap: US$725 million

Hyliion Holdings may be worth a closer look for investors interested in early stage power technology that is starting to gain real world validation. The company is still loss making and depends on external borrowing, yet it now has a $41.7 million U.S. Navy contract for multi megawatt KARNO systems. Management has raised 2026 revenue guidance to around $15 million and reports a growing pipeline with data center builders. Forecast revenue growth is described as very strong, although analysts do not yet expect profitability over the next three years, which raises execution and funding questions. That mix of high growth expectations, concentrated product risk and early traction with both hyperscalers and the military means Hyliion may represent a high risk candidate within this screener.

Hyliion’s early traction with hyperscalers and the U.S. Navy suggests the story around its fuel flexible power tech is still forming. Read the analysis report for Hyliion Holdings to see the one factor that could change how investors frame this entirely.

Seeking Fresh Alternatives Before They Fly

New ideas can move from under the radar to full momentum fast. Spot potential breakouts while the data still feels fresh and before the crowd reacts.

• Spot potential trend leaders early by tracking cash rich businesses in the list of solid balance sheet and fundamentals (51 results) while valuations and balance sheets still look workable.
• Follow structural shifts in computing by scanning the 55 AI infrastructure stocks that could support rising data demand while these stocks are still building momentum.
• Prepare for possible sector rotations by checking the 20 high quality undiscovered gems that combine quality fundamentals with prices the wider market has not fully focused on yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.